臺灣博碩士論文加值系統

厚朴酚（magnolol）為一水難溶性之多酚類，從木蘭科植物厚朴 Magnolia officinalis 之莖皮、根皮及枝皮所分離出的成分，具有抗氧化、抗發炎、抗腫瘤、抗菌、抗氣喘、心臟保護作用及胃腸道保護作用等優越的藥理活性。然生體可用率低，本研究擬採用固體分散的技術，來增加厚朴酚之水中溶解度及體外溶離率，以期提高口服吸收。
首先採用多種增溶劑測試其於水中對厚朴酚之增溶作用，結果顯示普維酮K-30及HP-β-環糊精等具有顯著的效果。故本研究即選用普維酮K-30及HP-β-環糊精為載體，以熱熔法或溶媒蒸散法製成固體分散物，再經示差掃描熱分析、傅式轉換紅外線光譜分析、粉末X光繞射分析及電子顯微鏡掃描分析，得知在適當比例下，厚朴酚可與此兩種載體形成非晶形的產物，但由體外溶離試驗的比較，則顯現普維酮K-30之固體分散物之溶離效果較好。另在紐西蘭白兔之口服吸收比較上，在血峰濃度（Cmax）及血藥面積（AUC）方面，此固體分散物比單獨厚朴酚分別增加45％及83％，確實可顯著地提高生體可用率。
本研究中發現熱熔法比溶媒蒸散法更易形成非晶形之厚朴酚固體分散物，且熱熔法兼具便利、簡單、經濟、環保等優點，因此可提供業界將來欲開發厚朴酚為口服劑型時之參考。

Magnolol, a water-insoluble polyphenol, were isolated from Magnolia officinalis and reported to possess many beneficial pharmacological activities including anti-oxidation, anti-inflammatory, anti-thrombus, anti-carcinogenic, antibacterial and protecting gastro-intestinal tract. However, its oral absorption is poor and erratic that many offend its efficiency. In this paper, we attempted to enhance the solubility and dissolution of magnolol by the formation of amorphous solid dispersionwith water-solable carrier and thereby could tried to render its utilization in oral absorption more efficient in clinic.
Among of the investigated carries, povidone K-30 and HP-β-cyclodextrin were found to have significant solubility enhancing effect on the magnolol. Therefore, the solid dispersions （SD） of magnolol were prepared by comelting or solvent evaporating method with povidone K-30 or HP-β-cyclodextrin and the characterization of the SD were assessed by the differential scanning calorimetry, Fourier transformation infrared spectrophotometry, powder X-ray diffraction and scanning electron microscopy. It was found that the solid dispersion would be an amorphous when the sufficient amount of carrier was used.
The SD prepared from the povidone K-30 was found having the best dissolution rate than that of prepared from HP-β-cyclodextrin or the intact drug. The pharmacokinetics of oral absorption of magnolol in rabbits were also significantly enhanced ( 45％ in Cmax or 83％ in AUC, respectively) when the SD was administered to compared with the intact drug.

In this study, we had found that the comelting methond was easier to form the amorphous amagnolol solid dispersion than the solvent evaporating method. On the other hand, the former also had the benefits of being feasible, economic, safety and environmental protection. In practice, if the oral solid dosage form of magnolol would be expected to have more efficiency, this proposed method was worthy of paying more attention to refer.

目 錄
內文目錄 I
附圖目錄 III 附表目錄 IX 中文摘要 XII 英文摘要 XIV
內文目錄
第一章 緒言 1
第二章 總論 3 第一節 固體分散技術之研究發展 3
第二節 厚朴酚之結構及理化性質 15
第三節 厚朴酚之藥理考察 16
第三章 實驗部分 20 第一節 實驗材料及儀器 20
一、 實驗試藥 20 二、 器材及儀器設備 23 三、 溶液製備 25 四、 實驗動物 26
第二節 實驗方法 27 一、厚朴酚之定量分析 27
二、厚朴酚於不同溶媒中之飽和溶解度 28
三、增溶劑對厚朴酚之增溶作用 29
四、載體與厚朴酚於固態下之作用 29
五、厚朴酚之固體分散物 29

第四章 結果與討論 39 一、分析方法之確效 39
二、厚朴酚於不同溶媒中之飽和溶解度 39
三、增溶劑對厚朴酚之增溶作用 40
四、載體與厚朴酚物理混合物之熱分析研究 41
五、固體分散物之物化性質探討 42
六、厚朴酚及其固體分散物之安定性試驗 49
七、厚朴酚固體分散物之溶離度試驗 50
八、厚朴酚固體分散物在兔體內口服吸收的比較 51
第五章 結論 55
參考文獻 102
附錄 121

參 考 文 獻
1. Perez Rosa Ana, Iglesias Maria Teresa, Pueyo Encarnacion, Gonzalez Montserrat, de Lorenzo Cristina. Amino acid composition and antioxidant capacity of Spanish honeys. Journal of Agricultural & Food Chemistry. 55(2):360-5, 2007.
2. Kamalakkannan N, Stanely Mainzen Prince P. Rutin improves the antioxidant status in streptozotocin-induced diabetic rat tissues. Molecular & Cellular Biochemistry. 293(1-2):211-9, 2006.
3. Cui Tong. Nakamura Kozo, Tian Su. Kayahara Hirpshi, Tian Yi-Ling. Polyphenolic content and physiological activities of Chinese hawthorn extracts. Bioscience, Biotechnology & Biochemistry. 70(12):2948-56, 2006.
4. Rangkadilok Nuchanart, Sitthimonchai Somkid, Worasuttayangkurn Luksamee, Mahidol Chulabhorn, Ruchirawat Mathuros, Satayavivad Jutamaad. Evaluation of free radical scavenging and antityrosinase activities of standardized longan fruit extract. Food & Chemical Toxicology. 45(2):328-36, 2007.
5. Wallace CH, Baczko I. Jones L, Fercho M, Light PE. Inhibition of cardiac voltage-gated sodium channels by grape polyphenols. British Journal of Pharmacology. 149(6):657-65, 2006.
6. Yamamoto Junichiro, Naemura Aki, Ura Mayumi, Ijiri Yoshinobu, Yamashita Tsutomu, Kurioka Akira, Koyama Akio. Testing various fruits for anti-thrombotic effect: i. Mulberries. Platelets. 17(8):555-64, 2006.
7. Schijlen Elio, Ric de Vos CH, Jonker Harry, van den Broeck Hetty, Molthoff Jos, van Tunen Arjen, Martens Stefa, Bovy Arnaud. Pathway engineering for healthy phytochemicals leading to the production of novel flavonoids in tomato fruit. Plant Biotechnology Journal. 4(4):433-44, 2006.
8. Mehendale Sangeeta R, Wang Chong-Zhi, Shao Zuo-Hui, Li Chang-Qing, Xie Jing-Tian, Aung Han H, Yuan Chun-Su.Chronic pretreatment with American ginseng berry and its polyphenolic constituents attenuate oxidant stress in cardiomyocytes. European Journal of Pharmacology. 553(1-3):209-14, 2006.
9. Lecumberri E, Mateos R, Ramos S, Alia M. Ruperez P, Goya L, Izquierdo-Pulido M, Bravo L. Characterization of cocoa fiber and its effect on the antioxidant capacity of serum in rats. Nutricion Hospitalaria. 21(5):622-8, 2006.
10. Hartman Richard E, Shah Aartie, Fagan Anne M, Schwetye Katherine E, Parsadanian Maia, Schulman Risa N, Finn Mary Beth, Holtzman David M. Pomegranate juice decreases amyloid load and improves behavior in a mouse model of Alzheimer''s disease. Neurobiology of Disease. 24(3):506-15, 2006.
11. Irine Dini, Gian Carlo Tenore, Antonio Dini. New polyphenol derivative in Ipomoea batatas tubers and its antioxidant activity. Journal of Agricultural & Food Chemistry. 54(23):8733-7, 2006.
12. Martin Antonio Ramón, Villegas Isabel, Sanchez-Hidalgo Marina, de la Lastra Catalina Alarcón. The effects of resveratrol, a phytoalexin derived from red wines, on chronic inflammation induced in an experimentally induced colitis model. British Journal of Pharmacology. 147(8):873-85, 2006.
13. Ekor Martins, Farombi Ebenezer Olatunde, Emerole Godwin O. Modulation of gentamicin-induced renal dysfunction and injury by the phenolic extract of soybean (Glycine max). Fundamental & Clinical Pharmacology. 20(3):263-71, 2006.
14. Li Li. Tsao Rong, Yang Raymond, Liu Chunming, Zhu Honghui, Young J,Christopher. Polyphenolic profiles and antioxidant activities of heartnut (Juglans ailanthifolia Var. cordiformis) and Persian walnut (Juglans regia L.). Journal of Agricultural & Food Chemistry. 54(21):8033-40, 2006.
15. Stapleton Paul D, Gettert Jasmine, Taylor Peter W. Epicatechin gallate, a component of green tea, reduces halotolerance in Staphylococcus aureus. International Journal of Food Microbiology. 111(3):276-9, 2006.
16. Tsao Rong, Yang Raymond, Xie Sheery, Sockovie Emily, Khanizadeh Shahrokh. Which polyphenolic compounds contribute to the total antioxidant activities of apple? Journal of Agricultural & Food Chemistry. 53(12):4989-95, 2005.
17. Yen Wen-Jye, Wang Bor-Sen, Chang Lee-Wen, Duh Pin-Der. Antioxidant properties of roasted coffee residues. Journal of Agricultural & Food Chemistry. 53(7):2658-63, 2005.
18. Wu Yu-Tse, Lin Lie-Chwen, Tsai Tung-Hu. Simultaneous determination of honokiol and magnolol in Magnolia officinalis by liquid chromatography with tandem mass spectrometric detection. Biomedical Chromatography. 20(10):1076-81, 2006.
19. Chen Gang, Xu Xuejiao, Zhu Yizhun, Zhang Luyan, Yang Pengyuan. Determination of honokiol and magnolol in cortex Magnoliae Officinalis by capillary electrophoresis with electrochemical detection. Journal of Pharmaceutical & Biomedical Analysis. 41(4):1479-84, 2006.
20. Lu Y. Sun C, Pan Y. A comparative study of upright counter-current chromatography and high-performance liquid chromatograpohy for preparative isolation and purification ofphenolic compounds from Magnoliae officinalis. Journal of Separation Science. 29(3):351-7, 2006.
21. Amidon Gordon L, Lennernas Hans, Shah Vinod P, Crison John R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharmaceutical Research. 12(3):413-20, 1995.
22. Gupta Manish K, Vanwert Adam, Bogner Robin H. Formation of physically stable amorphous drugs by milling with Neusilin. Journal of Pharmaceutics science. 92 : 536-551,2003.
23. Wadke D.A, Serajuddin A.T.M, Jacobson H. Preformulation testing.
In Pharmaceuticl Dosage Forms: Tablets , Vol.l ; Lieberman,H.A; Lachman,L.; Schwartz,J.B. ,Eds.; Marcel Dekker : New York, pp1-73;1989
24. Sekiguchi K, Obi N. Studies on absorption of eutectic mixture. I.A comparison of the behavior of eutectic mixture of sulfathiazole and that of ordinary sulfathiazole in man. Chem.Pharm.Bull. 9,866-872,1961
25. Chiou. W.L, Riegelman S. Pharmaceutical applications of solid dispersion systems. J.Phatm.Sci. 60,1281-1302,1971
26. Goldberg, A.H.Gibaldi, M.Kanig, J.L. Increasing dissolution rates and gastrointestinal absorption of drug via solid solution and eutectic mixture II. Experimental evaluation of eutectic mixture : urea-acetaminophen system. J.Phatm.Sci. 55,482-487,1966.
27. Goldberg, A.H.Gibaldi, M.Kanig, J.L. Increasing dissolution rates and gastrointestinal absorption of drug via solid solution and eutectic mixture III. Experimental evaluation of eutectic mixture : griseofulvin – succnic acid solution. J.Pharm.Sci. 55 487-492,1966
28. Liu Chen, Wu Junhua, Shi Bin, Zhang Yuanxing, Gao Tiankun, Pei Yuanying. Enhancing the bioavailability of cyclosporine a using solid dispersion containing polyoxyethylene (40) stearate. Drug Development & Industrial Pharmacy. 32(1):115-23, 2006.
29. Yuksel Nilüfer, Karata Aysegül, Ozkan Yalçın, Savaer Ayhan, Ozkan Sibel A, Baykara Tamer. Enhanced bioavailability of piroxicam using Gelucire 44/14 and labrasol: in vitro and in vivo evaluation. European Journal of Pharmaceutics & Biopharmaceutics. 56(3):453-9, 2003.
30. 王桂和,具腸包衣藥物的固體分散物及其在製劑中的應用,中國藥學雜誌, 24（4）,198, 1989
31. Zhu Yucun, Shah Navnit H, Malick A, Waseem, Infeld Martin H, McGinity James W. Controlled release of a poorly water-soluble drug from hot-melt extrudates containing acrylic polymers. Drug Development & Industrial Pharmacy. 32(5):569-83, 2006.
32. Ahuja Naveen, Katare Om Prakash, Singh Bhupinder. Studies on dissolution enhancement and mathematical modeling of drug release of a poorly water-soluble drug using water-soluble carriers. European Journal of Pharmaceutics & Biopharmaceutics. 65(1):26-38, 2007.
33. Ren Fuzheng, Jing Qiufang, Tang Yanhui, Shen Yongjia, Chen Jialei, Gao Feng. Cui Jingbin. Characteristics of bicalutamide solid dispersions and improvement of the dissolution. Drug Development & Industrial Pharmacy. 32(8):967-72, 2006.
34. Huang Jingjun, Wigent Rodney J, Schwartz Joseph B. Nifedipine molecular dispersion in microparticles of ammonio methacrylate copolymer and ethylcellulose binary blends for controlled drug delivery: effect of matrix composition. Drug Development & Industrial Pharmacy. 32(10):1185-97, 2006.
35. Huang Jingjun, Wigent Rodney J, Bentzley Catherine M, Schwartz Joseph B. Nifedipine solid dispersion in microparticles of ammonio methacrylate copolymer and ethylcellulose binary blend for controlled drug delivery. Effect of drug loading on release kinetics. International Journal of Pharmaceutics. 319(1-2):44-54, 2006.
36. Dangprasirt P, Pongwai S. Development of diclofenac sodium controlled release solid dispersion powders and capsules by freeze drying technique using ethylcellulose and chitosan as carriers. Drug Development & Industrial Pharmacy. 24(10):947-53, 1998.
37. Takada K, Oh-hashi M, Furuya Y, Yoshikawa H, Muranishi S. Enteric solid dispersion of ciclosporin A (CiA) having potential to deliver CiA into lymphatics. Chemical & Pharmaceutical Bulletin. 37(2):471-4, 1989.
38. Wang Liang, Cui Fu De, Hayase Tomokazu, Sunada Hisakazu. Preparation and evaluation of solid dispersion for nitrendipine- carbopol and nitrendipine-HPMCP systems using a twin screw extruder. Chemical & Pharmaceutical Bulletin. 53(10):1240-5, 2005.
39. Verheyen S, Blaton N, Kinget R, Van den Mooter G. Mechanism of increased dissolution of diazepam and temazepam from polyethylene glycol 6000 solid dispersions. International Journal of Pharmaceutics. 249(1-2):45-58, 2002.
40. Chutimaworapan S, Ritthidej GC,Yonemochi E, Oguchi T, Yamamoto K. Effect of water-soluble carriers on dissolution characteristics of nifedipine solid dispersions. Drug Development & Industrial Pharmacy. 26(11):1141-50, 2000.
41. Karavas Evangelos, Ktistis Georgios, Xenakis Aristotelis, Georgarakis Emmanouel. Effect of hydrogen bonding interactions on the release mechanism of felodipine from nanodispersions with polyvinylpyrrolidone. European Journal of Pharmaceutics & Biopharmaceutics. 63(2):103-14, 2006.
42. Jun Seoung Wook, Kim Min-Soo, Jo Guk Hyun, Lee Sibeum, Woo Jong Soo, Park Jeong Sook, Hwang Sung-Joo. Cefuroxime axetil solid dispersions prepared using solution enhanced dispersion by supercritical fluids. Journal of Pharmacy & Pharmacology. 57(12):1529-37, 2005.
43. Karavas Evangelos, Ktistis Georgios, Xenakis Aristotelis, Georgarakis Emmanouel. Miscibility behavior and formation mechanism of stabilized felodipine- polyvinylpyrrolidone amorphous solid dispersions. Drug Development & Industrial Pharmacy. 31(6):473-89, 2005.
44. Gupta P, Bansal AK. Spray drying for generation of a ternary amorphous system of celecoxib, PVP, and meglumine. Pharmaceutical Development & Technology. 10(2):273-81, 2005.
45. Mallick S, Sahu A, Pal K. Dissolution behaviour of nalidixic acid solid dispersions using water soluble dispersion carriers. Acta Poloniae Pharmaceutica. 61(1):21-30, 2004.
46. Paradkar A, Ambike AA, Jadhav BK, Mahadik KR. Characterization of curcumin-PVP solid dispersion obtained by spray drying. International Journal of Pharmaceutics. 271(1-2):281-6, 2004.
47. Sethia S, Squillante E. Solid dispersion of carbamazepine in PVP K30 by conventional solvent evaporation and supercritical methods. International Journal of Pharmaceutics. 272(1-2):1-10, 2004.
48. Aso Yukio, Yoshioka Sumie, Kojima Shigeo. Molecular mobility-based estimation of the crystallization rates of amorphous nifedipine and phenobarbital in poly(vinylpyrrolidone) solid dispersions. Journal of Pharmaceutical Sciences. 93(2):384-91, 2004.
49. Yamashita Kazunari, Nakate Toshiomi, Okimoto Kazuto, Ohike Atsuo, Tokunaga Yuji, Ibuki Rinta, Higaki Kazutaka, Kimura Toshikiro. Establishment of new preparation method for solid dispersion formulation of tacrolimus. International Journal of Pharmaceutics. 267(1-2):79-91, 2003.
50. Mallick S, Sahoo A, Mitra SS. Preparation, physicochemical characterization and drug release studies of albendazole solid dispersions. Bollettino Chimico Farmaceutico. 142(4):180-6, 2003.
51. Palmieri GF, Cantalamessa F, Di Martino P, Nasuti C, Martelli S. Lonidamine solid dispersions: in vitro and in vivo evaluation. Drug Development & Industrial Pharmacy. 28(10):1241-50, 2002.
52. Chen Y, Zhang GG, Neilly J, Marsh K, Mawhinney D, Sanzgiri YD. Enhancing the bioavailability of ABT-963 using solid dispersion containing Pluronic F-68. International Journal of Pharmaceutics. 286(1-2):69-80, 2004.
53. Mehta KA, Kislalioglu MS, Phuapradit W, Malick AW, Shah NH. Multi-unit controlled release systems of nifedipine and nifedipine:pluronic F-68 solid dispersions: characterization of release mechanisms. Drug Development & Industrial Pharmacy. 28(3):275-85, 2002.
54. Ho Hsiu-O, Chen Chia-Nan, Sheu Ming-Thau. Influence of pluronic F-68 on dissolution and bioavailability characteristics of multiple-layer pellets of nifedipine for controlled release delivery. Journal of Controlled Release. 68(3):433-40, 2000.
55. Pan RN, Chen JH, Chen RR. Enhancement of dissolution and bioavailability of piroxicam in solid dispersion systems. Drug Development & Industrial Pharmacy. 26(9):989-94, 2000.
56. Ma X, Rong SK, Wu QQ, Zhou GX. X-ray diffraction studies on tolbutamide solid dispersion. Yao Hsueh Hsueh Pao - Acta Pharmaceutica Sinica. 27(2):144-9, 1992.
57. Bloch DW, Elegakey MA, Speiser PP. Solid dispersion of chlorthalidone in urea phase diagram and dissolution characteristics. Pharmaceutica Acta Helvetiae. 57(8):231-5, 1982.
58. Ford JL, Stewart AF, Rubinstein MH. The assay and stability of chlorpropamide in solid dispersion with urea. Journal of Pharmacy & Pharmacology. 31(11):726-9, 1979.
59. Summers MP. Glass formation in barbiturates and solid dispersion systems of barbiturates with citric acid. Journal of Pharmaceutical Sciences. 67(11):1606-10, 1978.
60. Summers MP, Enever RP. Preparation and properties of solid dispersion system containing citric acid and primidone. Journal of Pharmaceutical Sciences. 65(11):1613-7, 1976.
61. Van Drooge DJ, Hinrichs WL, Frijlink HW. Anomalous dissolution behaviour of tablets prepared from sugar glass-based solid dispersions. Journal of Controlled Release. 97(3):441-52, 2004.
62. Allen LV, Levinson RS, Martono DD. Dissolution rates of hydrocortisone and prednisone utilizing sugar solid dispersion systems in tablet form. Journal of Pharmaceutical Sciences. 67(7):979-81, 1978.
63. Valizadeh H, Nokhodchi A, Qarakhani N, Zakeri-Milani P, Azarmi S, Hassanzadeh D, Lobenberg R. Physicochemical characterization of solid dispersions of indomethacin with PEG 6000, Myrj 52, lactose, sorbitol, dextrin, and Eudragit E100. Drug Development & Industrial Pharmacy. 30(3):303-17, 2004.
64. Arias MJ, Gines JM, Moyano JR, Rabasco AM. The application of solid dispersion technique with D-mannitol to the improvement in oral absorption of triamterene. Journal of Drug Targeting. 2(1):45-51, 1994.
65. Mirza Sabiruddin, Heinamaki Jyrki, Miroshnyk Inna, Rantanen Jukka, Christiansen Leena, Karjalainen Milja, Yliruusi Jouko. Understanding processing-induced phase transformations in erythromycin-PEG 6000 solid dispersions. Journal of Pharmaceutical Sciences. 95(8):1723-32, 2006.
66. Li L, AbuBaker O, Shao ZJ. Characterization of poly ( ethylene oxide ) as a drug carrier in hot-melt extrusion. Drug Development & Industrial Pharmacy. 32(8):991-1002, 2006.
67. Varshosaz Jaleh, Faghihian Hossein, Rastgoo Kobra. Preparation and characterization of metoprolol controlled-release solid dispersions. Drug Delivery. 13(4):295-302, 2006.
68. Chokshi RJ, Sandhu HK, Iyer RM, Shah NH, Malick AW, Zia H. Characterization of physico-mechanical properties of indomethacin and polymers to assess their suitability for hot-melt extrusion processs as a means to manufacture solid dispersion/solution. Journal of Pharmaceutical Sciences. 94(11):2463-74, 2005
69. Abd el-Fattah S, Boraie NA, Hassan HM. Enhancement of dissolution rate of hydrochlorothiazide via solid dispersion. Pharmazie. 41(11):790-3, 1986.
70. Ozkan Yalçın, Doganay Nazan, Dikmen Necati, Iimer A kın. Enhanced release of solid dispersions of etodolac in polyethylene glycol. Farmaco. 55(6-7):433-8, 2000.
71. Trapani G, Cutrignelli A, Latrofa A, Franco M, Serra M, Pisu MG, Biggio G, Liso G. Valproic acid-hydrophilic cyclodextrin complexes and valproic acid-solid dispersions: evaluation of their potential pharmaceutical use. Drug Development & Industrial Pharmacy. 30(1):53-64, 2004.
72. Shin Sang-Chul, Kim Jin. Physicochemical characterization of solid dispersion of furosemide with TPGS. International Journal of Pharmaceutics. 251(1-2):79-84, 2003.
73. Abdul Fattah M, Hargva N. Preparion and in vitro evaluation of solid dispersion of halfantrine. Internation journal of pharmaceutics. 235 : 17-33, 2002
74. Damian Festo, Norbert Blaton, Lieve Naesens, Jan Balzarini, Renaat Kinget, Patrick Augustijns, Mooter Guy Van den. Physicochemical characterization of solid dispersions of the antiviral agent UC-781 with polyethylene glycol 6000 and Gelucire 44/14. European Journal of Pharmaceutics Science. 10(4) : 311-322, 2000.
75. Pozzi, Ongo, Azzarini, Arenzi. Formulation of Ubidecarenone with improved bioavalibility. European Journal of Pharmaceutics Science
37: 243-246, 1991
76. Murali Mohan Babu GV, Prasad ChD, Ramana Murthy KV. Evaluation of modified gum karaya as carrier for the dissolution enhancement of poorly water-soluble drug nimodipine. International Journal of Pharmaceutics. 234(1-2):1-17, 2002.
77. Watanabe Tomoyuki, Hasegawa Susumu, Wakiyama Naoki, Kusai Akira, Senna Mamoru. Comparison between polyvinylpyrrolidone and silica nanoparticles as carriers for indomethacin in a solid state dispersion. International Journal of Pharmaceutics. 250(1):283-6, 2003.
78. Yano K, Takamatsu N, Yamazaki S, Sako K, Nagura S, Tomizawa S, Shimaya J, Yamamoto K. Crystal forms, improvements of dissolution and absorption of poorly water-soluble (R)-1-[2,3-dihydro-1-(2''-methylphenacyl)-2-oxo-5-phenyl-1H-1, 4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022). Yakugaku Zasshi - Journal of the Pharmaceutical Society of Japan. 116(8):639-46, 1996.
79. THE MERCK INDEX, THIRTEENTH EDITION, page 1019
80. Yang Shu-Er, Hsieh Ming-Tsuen, Tsai Tung-Hu, Hsu Shih-Lan . Effector mechanism of magnolol-induced apoptosis in human lung squamous carcinoma CH27 cells. British Journal of Pharmacology. 138(1):193-201, 2003.
81. Zhong Wen-Bin, Wang Chih-Yuan, Ho Kuo-Jang, Lu Fung-Jou, Chang Tien-Chun, Lee Wen-Sen. Magnolol induces apoptosis in human leukemia cells via cytochrome c release and caspase activation. Anti-Cancer Drugs. 14(3):211-7, 2003.
82. Lin Shyr-Yi, Liu Jean-Dean, Chang Hui-Chiu, Yeh Shauh-Der, Lin Chien-Huang, Lee Wen-Sen. Magnolol suppresses proliferation of cultured human colon and liver cancer cells by inhibiting DNA synthesis and activating apoptosis. Journal of Cellular Biochemistry. 84(3):532-44, 2002.
83. Homma M, Minami M, Taniguchi C, Oka K, Morita S, Niitsuma T, Hayashi T. Inhibitory effects of lignans and flavonoids in saiboku-to, a herbal medicine for bronchial asthma, on the release of leukotrienes from human polymorphonuclear leukocytes. Planta Medica. 66(1):88-91, 2000.
84. Yu-Chi Hou, Pei-Dawn Lee Chao, Shiouh-Yi Chen. Honokiol and magnolol increased hippocampal acetylcholine release in freely-moving rats. American Journal of Chinese Medicine, Vol.28, Nos. 3-4, pp. 379-384,2000.
85. Tianjin Institute of Pharmaceutical Research. Plant Active Constituent Database. Beijing: China Medico-Pharmaceutical Sciences and Technology Publishing House, 2000.
86. Lin MH, Chao HT, Hong CY. Magnolol protects human sperm motility against lipid peroxidation: a sperm head fixation method. Archives of Andrology. 34(3):151-6, 1995.
87. Hong CY, Huang SS, Tsai SK. Magnolol reduces infarct size and suppresses ventricular arrhythmia in rats subjected to coronary ligation. Clinical & Experimental Pharmacology & Physiology. 23(8):660-4, 1996.
88. Lee Yen-Mei, Hsiao George, Chen Huey-Rue, Chen Yao-Chang, Sheu Joen-Rong, Yen Mao-Hsiung. Magnolol reduces myocardial ischemia/reperfusion injury via neutrophil inhibition in rats. European Journal of Pharmacology. 422(1-3):159-67, 2001.
89. Huang CH, Hong CY, Tsai SK, Lai ST. Effect of magnolol on coronary vascular resistance in rabbits: measurement with pulsed Doppler velocimetry. Journal of the Formosan Medical Association. 99(7):554-8, 2000.
90. Chen Yuh-Lien, Lin Kuan-Fu, Shiao Ming-Shi, Chen Ya-Ting, Hong Chuang-Ye, Lin Shing-Jong. Magnolol, a potent antioxidant from Magnolia officinalis, attenuates intimal thickening and MCP-1 expression after balloon injury of the aorta in cholesterol-fed rabbits. Basic Research in Cardiology. 96(4):353-63, 2001.
91. Chen Yung-Hsiang, Lin Shing-Jong, Chen Jaw-Wen, Ku Hung-Hai, Chen Yuh-Lien. Magnolol attenuates VCAM-1 expression in vitro in TNF-alpha-treated human aortic endothelial cells and in vivo in the aorta of cholesterol-fed rabbits. British Journal of Pharmacology. 135(1):37-47, 2002.
92. Lin Yi-Ruu, Chen Hwei-Hsien, Ko Chien-Hsin, Chan Ming-Huan. Neuroprotective activity of honokiol and magnolol in cerebellar granule cell damage. European Journal of Pharmacology. 537(1-3):64-9, 2006.
93. Matsui Nobuaki, Nakashima Hiroshi, Ushio Yuki, Tada Toshimasa, Shirono Akiko, Fukuyama Yoshiyasu, Nakade Kousuke, Zhai Haifeng, Yasui Yumiko, Fukuishi Nobuyuki, Akagi Reiko, Akagi Masaaki. Neurotrophic effect of magnolol in the hippocampal CA1 region of senescence-accelerated mice (SAMP1). Biological & Pharmaceutical Bulletin. 28(9):1762-5, 2005.
94. Wu Chieh-His, Chen Chih-Wen, Chen Ho-Chih, Chang Weng-Cheng, Shu Min-Ji, Hung Jui-Sung. Elucidating the inhibitory mechanisms of magnolol on rat smooth muscle cell proliferation. Journal of Pharmacological Sciences. 99(4):392-9, 2005.
95. Fong Wang-Fun, Tse Anfernee Kai, Poon Ka-Hung, Wang Cheng. Magnolol and honokiol enhance HL-60 human leukemia cell differentiation induced by 1,25-dihydroxyvitamin D3 and retinoic acid. International Journal of Biochemistry & Cell Biology. 37(2):427-41, 2005.
96. Shen Yuh-Chiang, Sung Yen-Jen, Chen Chieh-Fu. Magnolol inhibits Mac-1 (CD11b/CD18)-dependent neutrophil adhesion: relationship with its antioxidant effect. European Journal of Pharmacology. 343(1):79-86, 1998.
97. Son HJ, Lee HJ, Yun-Choi HS, Ryu JH. Inhibitors of nitric oxide synthesis and TNF-alpha expression from Magnolia obovata in activated macrophages. Planta Medica. 66(5):469-71, 2000.
98. Matsuda Hisashi, Kageura Tadashi, Oda Mamiko, Morikawa Toshio, Sakamoto Yasuko, Yoshikawa Masayuki. Effects of constituents from the bark of Magnolia obovata on nitric oxide production in lipopolysaccharide-activated macrophages. Chemical & Pharmaceutical Bulletin. 49(6):716-20, 2001.
99. Lee J, Jung E, Park J, Jung K, Lee S, Hong S, Park J, Park E, Kim J, Park S, Park D. Anti-inflammatory effects of magnolol and honokiol are mediated through inhibition of the downstream pathway of MEKK-1 in NF-kappaB activation signaling. Planta Medica. 71(4):338-43, 2005.
100. Chen JS, Chen YL, Greenberg AS, Chen YJ, Wang SM. Magnolol stimulates lipolysis in lipid-laden RAW 264.7 macrophages. Journal of Cellular Biochemistry. 94(5):1028-37, 2005.
101. Huang Shih-Horng, Shen Wung-Jing, Yeo Hui-Lin, Wang Seu-Mei. Signaling pathway of magnolol-stimulated lipolysis in sterol ester-loaded 3T3-L1 preadipocyes. Journal of Cellular Biochemistry. 91(5):1021-9, 2004.
102. Shih Hsin-Chin, Wei Yau-Huei, Lee Chen-Hsen. Magnolol alters the course of endotoxin tolerance and provides early protection against endotoxin challenge following sublethal hemorrhage in rats. Shock. 22(4):358-63, 2004.
103. Park Junho, Lee Jongsung, Jung Eunsun, Park Yumi, Kim Kukhyun, Park Byunghwa, Jung Kwangseon, Park Eunkyung, Kim Jieun, Park Deokhoon. In vitro antibacterial and anti-inflammatory effects of honokiol and magnolol against Propionibacterium sp. European Journal of Pharmacology. 496(1-3):189-95, 2004.
104. Teng CM, Chen CC, Ko FN, Lee LG, Huang TF, Chen YP, Hsu HY. Two antiplatelet agents from Magnolia officinalis. Thrombosis Research. 50(6):757-65, 1988.
105. Teng CM, Yu SM, Chen CC, Huang YL, Huang TF. EDRF-release and Ca+(+)-channel blockade by magnolol, an antiplatelet agent isolated from Chinese herb Magnolia officinalis, in rat thoracic aorta. Life Sciences. 47(13):1153-61, 1990.
106. Zhang Wei-Wei, Li Yan. Wang Xue-Qing, Tian Feng, Cao H, Wang MW, Sun QS. Effects of magnolol and honokiol derived from traditional Chinese herbal remedies on gastrointestinal movement. World Journal of Gastroenterology. 11(28):4414-8, 2005.
107. Bian Zhao Xiang, Zhang Gen Shui, Wong Ka Leung, Hu Xu Guang, Liu Liang, Yang Zhijun, Li Min. Inhibitory effects of magnolol on distal colon of guinea pig in vitro. Biological & Pharmaceutical Bulletin. 29(4):790-5, 2006.
108. Lin Yi-Ruu, Chen Hwei-Hsien, Ko Chien-Hsin, Chan Ming-Huan. Differential inhibitory effects of honokiol and magnolol on excitatory amino acid-evoked cation signals and NMDA-induced seizures. Neuropharmacology. 49(4):542-50, 2005.
109. Jun L, Jifang S, Miaoquan L, Yingyan L, Xihong X. Effects of Magnolol and Honokiol on the activities of streptococcal glucosyltransferases both in solution and adsorbed on an experimental pellicle. Letters in Applied Microbiology. 39(5):459-65, 2004.
110. Higuchi T, Connors KA. Advances in analytical chemistry and instrumentation. Interscience Publishers. 117-212, 1965.
111. G. Zingone, F. Rubessa. Preformulation study of the inclusion complex warfarin- β-cyclodextrin. International Journal of Pharmaceutics. 291,3-10,2005.
112. M. Echezarreta-Lo´peza, J.J. Torres-Labandeiraa,Castin˜eiras-Seijoa, L. Santana-Pen´ınb,a J.L. Vila-Jato. Complexation of the interferon inducer, bropirimine, with hydroxypropyl-b-cyclodextrin.European Journal of Pharmaceutical Sciences 9 381–386, 2000.
113. Li-Ping Ruan, Bo-Yang Yu, Guang-Miao Fu, Dan-ni Zhu. Improving the solubility of ampelopsin by solid dispersions and inclusion complexes. Journal of Pharmaceutical and Biomedical Analysis 38 457–464, 2005.
114. S. Sethia, E. Squillante. Solid dispersion of carbamazepine in PVP K30 by conventional solvent evaporation and supercritical methods. International Journal of Pharmaceutics 272, 1–10, 2004.
115. D.Q.M. Craig, The mechanisms of drug release from solid dispersions in water-soluble polymers, Int. J. Pharm. 231 131–144, 2002.
116.宋磊,張春娜,劉炯,張亞瓊,郭聖榮, 聚丙烯酸、聚乙烯吡咯烷酮對萘普生片釋放度的影响, 上海交通大學學报, Vo l. 39 No. 10 Oct. 2005　
117. Palmieri GF, Cantalamessa F, Di Martino P, Nasuti C, Martelli S. Lonidamine solid dispersions: in vitro and in vivo evaluation. Drug Development and Industrial Pharmacy. 28(10):1241-50, 2002.
118. Nubekura T, Ito Y, Cai H, Terao M, Hori R. Preparation and in vivo ocular absorption studies of disulfiram solid dispersion.Biological Pharmaceutical Bulletin. 23(5):616-20, 2000.